AstraZeneca PLC logo
AstraZeneca PLC (AZN)
Compare

AstraZeneca PLC (AZN) Price/FCF Ratio: 31.24

popular:market cap|pe ratio|revenue|price history|total return

Is AstraZeneca PLC’s Price/FCF ratio high or low?

AstraZeneca PLC's Price/FCF ratio of 31.24 is in line with its 5-year average of 33.18, around the middle of its 5-year range (20.79–55.01).

13.54% above its 12-month average of 27.51.

P/E Ratio|FCF Growth|Operating Margin|All Metrics

AZN Price/FCF Ratio Chart

AZN Price/FCF Ratio
31.24+30.66% 1Y
Zoom

AZN Average Price/FCF Ratio Chart

AZN Current vs Average Price/FCF Ratio Chart

AZN Price/FCF Ratio Metrics

PRICE/FCF RATIO

31.24

PRICE/FCF RATIO AVG TTM

27.51

PRICE/FCF RATIO AVG 3Y

30.61

PRICE/FCF RATIO AVG 5Y

33.18

PRICE/FCF RATIO AVG 10Y

58.55

PRICE/FCF RATIO AVG 15Y

46.69

PRICE/FCF RATIO AVG 20Y

37.67

CURRENT VS TTM AVG

+13.54%

CURRENT VS 3Y AVG

+2.05%

CURRENT VS 5Y AVG

-5.84%

CURRENT VS 10Y AVG

-46.64%

CURRENT VS 15Y AVG

-33.09%

CURRENT VS 20Y AVG

-17.06%

AZN Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
AstraZeneca PLC (AZN)$282.69B31.2427.5130.6133.18
Merck & Co., Inc. (MRK)$298.29B21.1518.1721.0221.59
UnitedHealth Group Incorporated (UNH)$368.30B18.7714.9626.3123.98
Amgen Inc. (AMGN)$191.09B22.4017.7119.4717.88
Thermo Fisher Scientific Inc. (TMO)$176.77B26.2930.5730.0130.66
AbbVie Inc. (ABBV)$397.12B19.1120.2717.0014.78
Gilead Sciences, Inc. (GILD)$156.28B15.4316.6513.8612.23
Abbott Laboratories (ABT)$156.15B21.2329.7233.5029.77
Pfizer Inc. (PFE)$149.18B15.8113.9119.4316.06
Intuitive Surgical, Inc. (ISRG)$146.23B52.4280.86163.16127.30

Free Cash Flow Valuation

P/FCF Ratio

31.2

FCF Yield

3.20%

AstraZeneca PLC Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

AstraZeneca PLC Price/FCF Ratio FAQ

What is the Price/FCF ratio for AstraZeneca PLC (AZN)?
The Price/FCF ratio for AZN stock is 31.24.
Is AstraZeneca PLC's Price/FCF ratio high or low?
AstraZeneca PLC's Price/FCF ratio of 31.24 is in line with its 5-year average of 33.18, around the middle of its 5-year range (20.79–55.01).
What is the TTM average Price/FCF ratio for AstraZeneca PLC (AZN)?
The TTM average Price/FCF ratio for AZN stock is 27.51.
What is the 3Y average Price/FCF ratio for AstraZeneca PLC (AZN)?
The 3Y average Price/FCF ratio for AZN stock is 30.61.
What is the 5Y average Price/FCF ratio for AstraZeneca PLC (AZN)?
The 5Y average Price/FCF ratio for AZN stock is 33.18.
What is the 10Y average Price/FCF ratio for AstraZeneca PLC (AZN)?
The 10Y average Price/FCF ratio for AZN stock is 58.55.
What is the 15Y average Price/FCF ratio for AstraZeneca PLC (AZN)?
The 15Y average Price/FCF ratio for AZN stock is 46.69.
What is the 20Y average Price/FCF ratio for AstraZeneca PLC (AZN)?
The 20Y average Price/FCF ratio for AZN stock is 37.67.

AstraZeneca PLC Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-1131.24
2026-06-1030.67
2026-06-0931.44
2026-06-0831.11
2026-06-0531.87
2026-06-0431.16
2026-06-0330.21
2026-06-0230.41
2026-06-0130.80
2026-05-2931.82
2026-05-2831.76
2026-05-2731.82
2026-05-2632.08
2026-05-2232.05
2026-05-2132.52
2026-05-2032.13
2026-05-1931.64
2026-05-1831.52
2026-05-1531.12
2026-05-1431.70
2026-05-1332.17
2026-05-1231.63
2026-05-1131.17
2026-05-0831.34
2026-05-0731.28
2026-05-0631.69
2026-05-0531.06
2026-05-0431.44
2026-05-0131.66
2026-04-3032.11
2026-04-2931.74
2026-04-2827.58
2026-04-2727.71
2026-04-2428.04
2026-04-2328.41
2026-04-2228.78
2026-04-2128.93
2026-04-2029.65
2026-04-1730.26
2026-04-1629.62
2026-04-1529.73
2026-04-1430.20
2026-04-1329.88
2026-04-1030.15
2026-04-0930.29
2026-04-0830.18
2026-04-0729.67
2026-04-0629.97
2026-04-0230.07
2026-04-0129.66
2026-03-3129.14
2026-03-3028.65
2026-03-2727.84
2026-03-2627.10
2026-03-2527.65
2026-03-2427.45
2026-03-2327.20
2026-03-2027.13
2026-03-1927.92
2026-03-1827.84
2026-03-1728.26
2026-03-1628.37
2026-03-1328.06
2026-03-1228.44
2026-03-1128.56
2026-03-1028.81
2026-03-0928.80
2026-03-0628.70
2026-03-0529.18
2026-03-0429.78
2026-03-0329.81
2026-03-0230.10
2026-02-2730.80
2026-02-2630.14
2026-02-2530.41
2026-02-2430.53
2026-02-2328.70
2026-02-2028.60
2026-02-1929.21
2026-02-1829.22
2026-02-1729.34
2026-02-1328.78
2026-02-1228.64
2026-02-1128.67
2026-02-1027.04
2026-02-0926.33
2026-02-0627.03
2026-02-0526.21
2026-02-0426.25
2026-02-0325.81
2026-02-0226.38
2026-01-3026.20
2026-01-2925.65
2026-01-2826.30
2026-01-2726.34
2026-01-2625.07
2026-01-2324.86
2026-01-2225.14
2026-01-2124.51
2026-01-2025.65
2026-01-1626.77
2026-01-1526.44
2026-01-1426.64
2026-01-1326.42
2026-01-1225.97
2026-01-0926.75
2026-01-0826.40
2026-01-0726.72
2026-01-0626.68
2026-01-0525.08
2026-01-0225.58
2025-12-3124.58
2025-12-3025.33
2025-12-2926.20
2025-12-2625.39
2025-12-2426.10
2025-12-2325.63
2025-12-2225.31
2025-12-1925.38
2025-12-1825.28
2025-12-1725.87
2025-12-1625.58
2025-12-1525.75
2025-12-1225.16
2025-12-1125.29
2025-12-1025.48
2025-12-0925.08
2025-12-0825.34
2025-12-0525.14
2025-12-0425.22
2025-12-0325.67
2025-12-0225.08
2025-12-0125.26
2025-11-2825.73
2025-11-2626.40
2025-11-2526.29
2025-11-2425.58
2025-11-2125.57
2025-11-2024.91
2025-11-1925.18
2025-11-1824.53
2025-11-1724.54
2025-11-1424.48
2025-11-1324.86
2025-11-1224.60
2025-11-1124.53
2025-11-1024.49
2025-11-0723.27
2025-11-0623.67
2025-11-0529.00
2025-11-0429.53
2025-11-0328.93
2025-10-3129.45
2025-10-3029.43
2025-10-2929.25
2025-10-2829.59
2025-10-2729.31
2025-10-2429.26
2025-10-2330.06
2025-10-2229.82
2025-10-2130.07
2025-10-2029.84
2025-10-1730.54
2025-10-1630.22
2025-10-1530.03
2025-10-1430.22
2025-10-1330.20
2025-10-1030.26
2025-10-0930.35
2025-10-0830.75
2025-10-0730.38
2025-10-0630.79
2025-10-0330.47
2025-10-0229.43
2025-10-0129.05
2025-09-3026.72
2025-09-2926.11
2025-09-2626.12
2025-09-2526.76
2025-09-2426.63
2025-09-2326.94
2025-09-2228.02
2025-09-1927.59
2025-09-1827.41
2025-09-1727.88
2025-09-1627.34
2025-09-1527.62
2025-09-1228.51
2025-09-1128.95
2025-09-1028.62
2025-09-0928.69
2025-09-0829.15
2025-09-0529.40
2025-09-0428.95
2025-09-0329.00
2025-09-0228.71
2025-08-2928.79
2025-08-2828.27
2025-08-2728.71
2025-08-2628.65
2025-08-2529.12
2025-08-2228.07
2025-08-2128.76
2025-08-2028.20
2025-08-1928.43
2025-08-1828.67
2025-08-1527.79
2025-08-1427.83
2025-08-1327.57
2025-08-1226.50
2025-08-1126.11
2025-08-0825.33
2025-08-0726.31
2025-08-0626.57
2025-08-0526.86
2025-08-0426.86
2025-08-0126.36
2025-07-3126.34
2025-07-3027.82
2025-07-2926.89
2025-07-2823.24
2025-07-2523.44
2025-07-2423.70
2025-07-2323.76
2025-07-2222.89
2025-07-2122.53
2025-07-1822.19
2025-07-1722.34
2025-07-1622.91
2025-07-1522.65
2025-07-1423.09
2025-07-1122.62
2025-07-1023.16
2025-07-0922.81
2025-07-0822.61
2025-07-0723.01
2025-07-0322.69
2025-07-0223.21
2025-07-0122.53
2025-06-3022.54
2025-06-2722.29
2025-06-2622.57
2025-06-2523.58
2025-06-2422.76
2025-06-2322.91
2025-06-2022.53
2025-06-1823.16
2025-06-1722.74
2025-06-1623.93
2025-06-1323.88
2025-06-1224.21
2025-06-1123.91
2025-06-1023.65
2025-06-0923.63
2025-06-0623.28
2025-06-0523.02
2025-06-0423.49
2025-06-0322.98
2025-06-0222.98
2025-05-3022.82

Showing the most recent 260 of 4,927 data points. The chart above shows the full history.

Related Metrics

P/E RatioFCF GrowthOperating MarginAll Metrics

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge
94,300 employees
www.astrazeneca.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Roland Soriot
View full financials